Stenting versus surgery for significant left main disease
Ralf E Harskamp1, Duk-Woo Park
1Department of Cardiology, VU University Medical Center, Amsterdam, The Netherlands.
Insights
Percutaneous coronary intervention (PCI) offers comparable outcomes to coronary artery bypass grafting (CABG) for left main coronary artery (LMCA) disease, with higher repeat revascularization rates. Guidelines support PCI for low-intermediate complexity and high-risk patients.
Area of Science:
- Cardiology
- Interventional Cardiology
- Cardiovascular Surgery
Background:
- Coronary artery bypass grafting (CABG) has historically been the standard treatment for significant left main coronary artery (LMCA) disease.
- Advances in percutaneous coronary intervention (PCI) with drug-eluting stents and pharmacology have made it a viable alternative for selected LMCA patients.
Purpose of the Study:
- To compare the effectiveness and safety of PCI versus CABG for treating significant LMCA disease.
- To evaluate clinical endpoints and the need for repeat revascularization in patients undergoing PCI or CABG.
Main Methods:
- Review of evidence from randomized clinical trials and real-world registries.
- Analysis of hard clinical endpoints including death, myocardial infarction, and stroke.
- Assessment of repeat revascularization rates post-intervention.
Main Results:
- PCI and CABG demonstrated comparable rates of death, myocardial infarction, and stroke at short- and mid-term follow-up.
- PCI was associated with a higher rate of repeat revascularization compared to CABG.
Conclusions:
- PCI is a reasonable alternative to CABG for LMCA disease in patients with low-to-intermediate anatomic complexity and those at increased surgical risk.
- Ongoing trials with newer-generation stents will further refine treatment strategies for LMCA disease.
Abstract:
For decades, coronary artery bypass grafting (CABG) has been the choice of revascularization strategy for significant left main coronary artery (LMCA) disease. However, with marked technological advances in less invasive percutaneous strategies, such as drug-eluting stents, and potent adjunctive pharmacology, percutaneous coronary intervention (PCI) has been increasingly accepted as an alternative to CABG for selected cases with LMCA disease. The available evidence from randomized clinical trials and adequately sized, real-world registries suggest that hard clinical endpoints (death, myocardial infarction, or stroke) were comparable between two treatment strategies at short- and mid-term follow-up, while higher rate of repeat revascularization are observed after PCI. Current guidelines state that PCI for LMCA disease is reasonable in patients with low to intermediate anatomic complexity and those who are at increased surgical risk. Ongoing large-sized clinical trials comparing newer-generation drug-eluting stents and CABG would provide important clinical insights to guide optimal strategy for patients with significant LMCA disease in the (near) future.
Related Concept Videos
Mitral Stenosis III: Medical Management
Coronary Artery Disease V: Interprofessional Care
Cardiac Catheterization III: Left Heart Catheterization
Peripheral Artery Disease III: Interprofessional Care
Angina IV: Management
Mitral Stenosis I: Introduction


